Action Plan: Actionable Research and Support …

1 Actionable Research and Support Activities Action PlanIdentified by the International Consortium for Personalised MedicineImprint EU grantThe Coordination and Support Action (CSA) ICPerMed Secretariat has received funding from the European Union s Horizon 2020 Research and innovation programme under grant agree-ment No 731366. Authors The ICPerMed Chairs, the Challenge Group Facilitators and the ICPerMed Secretariat: Ain Aaviksoo, Wolfgang Ballensiefen, Hemma Bauer, Ulrike Bu hoff, Monika Frenzel, Gaetano Guglielmi, Peter H ngaard Andersen, Daria Julkowska, Katja Kuhlmann, Maria Judit Molnar, Mair ad O Driscoll, on behalf of the International Consortium for Personalised Medicine (ICPerMed).

2 For a full list of ICPerMed members, see Annex 2. Acknowledgement ICPerMed would like to thank all experts who supported the Action Plan development by their valuable input via the challenge groups, questionnaires or interviews as well as the chal-lenge group workshop (February 2016) and the conference in Brussels (June 2016).Contact ICPerMed Secretariat Dr. Ulrike Bu hoff E-mail: ICPerMed webpage: Deutsches Zentrum f r Luft- und Raumfahrt e. V. (DLR) / DLR Project Management Agency, Department Health Linder H he, 51147 Cologne, GermanyDate March 2017 Design and layout: Katja Cloud | DLR Project Management AgencyLinks to external websites This ICPerMed Action Plan contains links to external third-party websites.

3 These links to third-party sites do not imply approval of their contents. DLR Project Management Agency has no influence on the current or future contents of these sites. We therefore accept no liability for the accessibility or contents of such websi-tes and no liability for damages that may arise as a result of the use of such content. Using the content and citation If you wish to use some of the written content, please make reference to: The ICPerMed Action Plan (2017).Contents Executive Summary 4 Introduction 5 Background to the establishment of ICPerMed 5 Overview of ICPerMed 6 How the Action Plan was developed 7 Research Activities Part A 8 Data 8 Technologies.

4 Methods and Processes 10 People 12 Cross-cutting 12 Research -supporting Activities Part B 13 Structures 13 Methods and Processes 13 People 14 Outlook 15 Annex 1: Summary table of Actionable items with time and scope information 16 Annex 2: List of ICPerMed members (as of March 2017) 184 ICPerMed ( ) is a newly established platform of over 30 European and international part-ners representing ministries, funding agencies and the European Commission (EC).

5 Since November 2016 the consortium is supported by a secre-tariat which is funded via a Coordination and Support Action (CSA) within the European Union s Horizon 2020 Research and innovation programme. The central aim of ICPerMed is to align and encourage joint efforts in personalised medicine Research and implementation. This will be achieved by diff-erent activities, such as meetings, workshops and congresses; surveys on personalised medicine programmes, successes and actions; strategic publications and joint preparation for the official launch, five working groups were established, with topics covering all aspects along the value chain and beyond:1.

6 Developing awareness and empowerment2. Integrating big data and ICT solutions 3. Translating basic to clinical Research and beyond4. Bringing innovation to market5. Shaping sustainable healthcareIn these groups, ICPerMed members and nominated experts worked hand in hand to develop a collection of actions to advance personalised medicine in all relevant areas and at all levels. This work was complemented by an international con-ference on personalised medicine organised in conjunction with the European Commission in June 2016.

7 ICPerMed s Action Plan is the culmination of these efforts. It represents an extract of this collection and lists Research activities (A1 A22) and Research -supporting activities (B1 B8) that are deemed to be ready for Action . The Action Plan is intended to be the blueprint for establishing Research activi-ties within the entire range of personalised medicine either at national level, European or international level. This Action Plan will feed into national and European strategic discussion of Research funders shaping their future programmes including both single actions and joint of the latter will be the European Research Area Network for personalised medicine (ERA-PerMed), which is in prep-aration and should begin work by end of 2017 with Joint Transnational Calls (JTCs)

8 On personalised medicine as a core important information and development in the context of ICPerMed will be available on the ICPerMed website and in upcoming Summary5 IntroductionPersonalised medicine uses information specific to an individual to target therapeutic and prevention strategies more accurately, putting citizens and patients at the centre of healthcare and innovation. Recent developments in areas such as molecular profiling, medical imaging and diagnostics are making personalised medicine a reality in healthcare.

9 In addition, a revolution in information technology has made it possible for researchers to collect and analyse ever greater quantities of data so that the impact is evident on the entire healthcare continuum, from health Research to patient care. Together with an improved understanding of the biological mechanisms and environmental interactions that govern disease progression and working with the policy and regulatory environment to encourage widespread use, these developments will change the way that healthcare is delivered in the to the establishment of ICPerMedThe International Consortium for Personalised Medicine (ICPerMed)

10 Builds on a number of previous initiatives in personalised medicine at EU and national level. In 2010, the European Commission organised a series of preparatory workshops, with a particular focus on the role of omics -related Research in personalised medicine ( genomics, pro-teomics, metabolomics, epigenomics, pharmacogenomics).1 This was followed a year later by a conference on European Perspectives in Personalised Medicine ,2 and further by the Personalised Medicine Conference In their Council conclusions on personalised medicine for patients published in December 2015,4 EU Health Ministers set out their views, 1 See European Commission Staff Working Document, Use of -omics technologies in the development of personalised medicine October 2013, (01)